PharmAla Issues Q3 Financial Statements

Core Insights - PharmAla Biotech Holdings Inc. has reported significant operational progress, including a large shipment of LaNeo MDMA to a U.S. distribution partner for clinical trials, and the completion of a manufacturing run for LaNeo Capsules in Australia [2][4] Financial Highlights - Customer deposits increased by $150,463 through Q3, with recognized revenue of $79,558, indicating a strong demand for clinical trial products [6] - Total expenses for the nine months ended May 31, 2025, were $2,117,495, compared to $1,085,458 for the same period in 2024, reflecting increased operational costs due to new hires and the cessation of capitalizing R&D costs [6] Company Overview - PharmAla focuses on the research, development, and manufacturing of MDXX class molecules, including MDMA, and aims to alleviate the backlog of clinical-grade MDMA for trials and commercial sales [5] - The company is recognized as the only provider of clinical-grade MDMA for patient treatments outside of clinical trials, emphasizing its regulatory relationships as a key to success in the psychedelics industry [5]